The MD Anderson Cancer Center at Cooper has partnered with behavioral health technology player Polaris Health Directions to start a pilot test using the Apple Watch that integrates patient behavioral data into electronic health records and population health data.
Japan's Takeda Pharmaceutical has reached an agreement to distribute Kaketsuken's influenza vaccine domestically in the 2015-2016 season as the government makes a major push to cover the elderly population.
Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' pipeline of antiviral treatments.
"Cover all the bases" is the theme of FierceDrugDelivery 's annual list of the top drug delivery partnerships. Finding 10 significant alliances that represent the full range of drug delivery advances was a challenge, and there are certainly other deals out there that are both novel and of high importance.
Boehringer Ingelheim has exercised an option to buy PXS4728A from Australia-based Pharmaxis and develop it for the treatment of the liver-related condition NASH with the candidate also showing potential in chronic obstructive pulmonary disease.
J. Craig Venter's Human Longevity (HLI) is joining forces with Cleveland Clinic for a human genomics collaboration aimed at disease discovery, a little more than a year after the company kicked off operations with the promise of building the world's biggest human gene-sequencing platform.
South Korea's Green Cross Holdings and POSCO Capital joined to buy a $7.5 million stake in U.S.-based Juventas Therapeutics, pushing a regenerative and biologics growth strategy that has seen recent deals in China and Russia.
Eli Lilly has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders.
Abbott and GE Healthcare are teaming up for a diagnostics collaboration aimed at improving treatment for patients with atrial fibrillation, planning to combine the companies' innovative technology to speed up diagnosis for individuals with heart rhythm disorders.
Foundation Medicine provided additional detail about Roche's multimillion-dollar investment in the cancer-focused molecular diagnostic company during its Q1 2015 earnings call.